Distinguishing HCM from Hypertensive Heart Disease
The key distinction is that HCM shows unexplained left ventricular hypertrophy (≥15 mm wall thickness) in the absence of another cause, while hypertensive heart disease develops secondary to chronic systemic hypertension—when wall thickness is in the modest range of 13-15 mm, use specific clinical markers including family history, genetic testing, pattern of hypertrophy, LV cavity size, and diastolic function to differentiate. 1
Clinical Differentiation
Diagnostic Criteria
HCM:
- Maximal LV wall thickness ≥15 mm (or 13-14 mm with positive family history or pathogenic sarcomere gene variant) 2
- Unexplained hypertrophy in absence of loading conditions
- Autosomal dominant inheritance with sarcomere protein mutations 1
- Often asymmetric septal hypertrophy, though one-third have segmental involvement 1
Hypertensive Heart Disease:
- LVH develops secondary to chronic elevated afterload
- History of poorly controlled hypertension 3
- More concentric, symmetric pattern of hypertrophy
- Regression possible with blood pressure control
Key Distinguishing Features
Favor HCM when present:
- Family history of HCM or sudden cardiac death 1, 4
- Sarcomeric gene mutations (>1400 mutations identified in 8+ genes) 1
- Smaller LV cavity dimensions 1
- Asymmetric septal hypertrophy (though not always present)
- Normal calculated LV mass despite focal severe hypertrophy 1
- Young age at presentation without hypertension history
Favor Hypertensive Heart Disease:
- Long-standing, documented hypertension
- Concentric remodeling pattern
- Larger LV cavity dimensions
- Absence of family history
- Regression with antihypertensive therapy
Advanced Imaging Differentiation
Cardiac MRI Parameters (Meta-Analysis Data)
HHD compared to HCM shows: 5
- Lower T1 mapping values (g = -0.469, P < 0.001)
- Lower extracellular volume (g = -0.417, P = 0.024) - indicating less diffuse interstitial fibrosis
- Lower LV mass index (g = -0.437, P < 0.001)
- Lower maximal LV wall thickness (g = -2.076, P < 0.001)
- Higher end-systolic volume index (g = 0.993, P < 0.001) - worse systolic function
- Higher end-diastolic volume index (g = 0.553, P < 0.001) - better preserved diastolic function
This reveals that hypertensive heart disease has significantly less myocardial fibrosis and less severe hypertrophy than HCM, but paradoxically worse systolic function. 5
Pathophysiology Differences
HCM Pathophysiology 4, 6
- Dynamic LVOT obstruction (present in two-thirds of patients)
- Basal obstruction: gradient ≥30 mmHg at rest
- Labile obstruction: provokable gradients ≥30 mmHg
- Threshold for intervention: ≥50 mmHg
- Systolic anterior motion (SAM) of mitral valve
- Diastolic dysfunction from impaired relaxation and increased stiffness
- Myocardial ischemia despite normal coronary arteries (microvascular dysfunction)
- Arrhythmogenic substrate for ventricular tachyarrhythmias
Hypertensive Heart Disease
- Concentric hypertrophy from chronic pressure overload
- No dynamic obstruction
- Diastolic dysfunction from increased afterload
- Potentially reversible with blood pressure control
Clinical Consequences & Risk Stratification
HCM-Specific Complications 1, 6
Three discrete pathways of progression:
- Sudden cardiac death - unpredictable ventricular tachyarrhythmias, most common in asymptomatic patients <35 years (including athletes)
- Progressive heart failure - exertional dyspnea with preserved or reduced ejection fraction
- Atrial fibrillation - increased stroke risk requiring anticoagulation
Management Implications
- ICD consideration for primary/secondary prevention based on risk factors
- Negative inotropes (beta-blockers, verapamil) for symptomatic LVOT obstruction
- Septal reduction therapy (surgical myectomy or alcohol ablation) for gradients ≥50 mmHg with refractory symptoms
- Genetic counseling and family screening
- Activity restrictions (competitive sports contraindicated)
- Anticoagulation for AF regardless of CHA₂DS₂-VASc score
Hypertensive heart disease requires:
- Aggressive blood pressure control
- Standard heart failure management
- No specific activity restrictions beyond general cardiovascular health
- Standard stroke risk assessment for AF
Common Diagnostic Pitfalls
Critical caveat: When wall thickness is 13-15 mm with concomitant hypertension, do not assume hypertensive etiology—actively investigate for HCM with echocardiographic pattern analysis, family history, and consider genetic testing. 1, 4 Missing HCM diagnosis has profound implications for sudden death risk, family screening, and activity restrictions.
Beware: Patients with HCM can have concomitant hypertension, creating diagnostic confusion. 3 The presence of hypertension does not exclude HCM—look for features disproportionate to blood pressure burden.
Remember: One-third of HCM patients have no LVOT obstruction at rest or with provocation, so absence of gradient does not exclude diagnosis. 1